Evidence map›Paper›PMID 10729137›Full record

ArticleJournal of virology2000

Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency.

H Berthomme, J Lokensgard, L Yang, T Margolis, L T Feldman

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  4. Review
  5. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle.Interdisciplinary perspectives on infectious diseases · 2010
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

H BerthommeDepartment of Microbiology, UCLA School of Medicine, Los Angeles, California 90095, USA.
J Lokensgard
L Yang
T Margolis
L T Feldman
University of California, Los Angeles · USSan Francisco Foundation · US

Funding

OCULAR INFECTION WITH THE HERPESVIRUSESR01EY010008 · NEI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI MARGOLIS, TODD P. · 1994 to 2003
$1.4M
HSV-1 GENE EXPRESSION IN LATENTLY INFECTED NEURONSR01AI028338 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FELDMAN, LAWRENCE T · 1989 to 2000
$252k
NEI NIH HHS EY10008NIAID NIH HHS AI28338
6 · The paper itself

Abstract

Herpes simplex virus type 1 (HSV-1) latent infection in vivo is characterized by the constitutive expression of the latency-associated transcripts (LAT), which originate from the LAT promoter (LAP). In an attempt to determine the functional parts of LAP, we previously demonstrated that viruses harboring a DNA fragment 3' of the LAT promoter itself were able to maintain detectable promoter expression throughout latency whereas viruses not containing this element could not (J. R. Lokensgard, H. Berthomme, and L. T. Feldman, J. Virol. 71:6714-6719, 1997). This element was therefore called a long-term expression element (LTE). To further study the role of the LTE, we constructed plasmids containing a DNA fragment encompassing the LTE inserted into a synthetic intron between the reporter lacZ gene and either the LAT or the HSV-1 thymidine kinase promoter. Transient-expression experiments with both neuronal and nonneuronal cell lines showed that the LTE locus has an enhancer activity that does not activate the cytomegalovirus enhancer but does activate the promoters such as the LAT promoter and the thymidine kinase promoter. The enhancement of these two promoters occurs in both neuronal and nonneuronal cell lines. Recombinant viruses containing enhancer constructs were constructed, and these demonstrated that the enhancer functioned when present in the context of the viral DNA, both for in vitro infections of cells in culture and for in vivo infections of neurons in mouse dorsal root ganglia. In the infections of mouse dorsal root ganglia, there was a very high level of promoter activity in neurons infected with viruses bearing the LAT promoter-enhancer, but this decreased after the first 2 or 3 weeks. By 18 days postinfection, neurons harboring latent virus without the enhancer showed no beta-galactosidase (beta-gal) staining whereas those harboring latent virus containing the enhancer continued to show beta-gal staining for long periods, extending to at least 6 months postinfection, the longest time examined.

Indexed as

Transcription, GeneticAnimalsAntigens, Viralbeta-GalactosidaseChlorocebus aethiopsEnhancer Elements, GeneticFemaleGanglia, SpinalGene Expression Regulation, ViralHerpes SimplexHerpesvirus 1, HumanImmunohistochemistryIntronsMiceNeuronsPlasmidsAntigens, Viralbeta-Galactosidase

Identifiers

PMID10729137
PMCPMC111871
OpenAlexW2114514769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.